This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Small-Cap Winners & Losers

Updated from 1:49 p.m. EDT

Targeted Genetics (TGEN) skyrocketed more than 66% Thursday after the biotech company swung to a fourth-quarter profit and sped past Street expectations. The Seattle-based company earned $808,000, or 8 cents a share, on revenue that more than doubled to $4 million. The company recorded a loss of $3.6 million, or 41 cents a share, in the year-ago period. The sole analyst's estimate called for a loss of 13 cents a share on $3.8 million in sales, according to Thomson Financial. Shares rose $1.70 to $4.27.

Misonix (MSON - Get Report) jumped after the Farmingdale, N.Y., company's Sonablate 500 product successfully removed cancerous tissue from prostate-cancer patients in a Britain-based study. In the study of the high-intensity ultrasound technology, test subjects exhibited 100% continence and potency in follow-up exams. Specifics on the trial weren't provided. Shares of Misonix rose 43 cents, or 7.4%, to $6.22.

Shares of etrials Worldwide (ETWC) gained after two unnamed European pharmaceutical companies agreed to etrials' clinical-trial software and services for wide-ranging clinical studies on depression and gaucher disease. Shares of the Morrisville, N.C.-based company climbed 33 cents, or 7.4%, to $4.82.

KMG America (KMA) lost 43.8% after A.M. Best cut the life-insurer's outlook to negative from stable, despite reiterating its A- (or excellent) financial-strength rating. The Minneapolis-based company said this may prevent it from competing in certain markets, and that it's "no longer comfortable" with prior 2007 earnings guidance until it finishes a review of the full consequences. Shares were down $3.80 to $4.87.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
TGEN $4.96 0.00%
MSON $13.29 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs